AU2012300641B2 - Method for detecting nucleosomes containing nucleotides - Google Patents
Method for detecting nucleosomes containing nucleotides Download PDFInfo
- Publication number
- AU2012300641B2 AU2012300641B2 AU2012300641A AU2012300641A AU2012300641B2 AU 2012300641 B2 AU2012300641 B2 AU 2012300641B2 AU 2012300641 A AU2012300641 A AU 2012300641A AU 2012300641 A AU2012300641 A AU 2012300641A AU 2012300641 B2 AU2012300641 B2 AU 2012300641B2
- Authority
- AU
- Australia
- Prior art keywords
- nucleosomes
- dna base
- nucleosome
- dna
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108010047956 Nucleosomes Proteins 0.000 title claims abstract description 420
- 210000001623 nucleosome Anatomy 0.000 title claims abstract description 419
- 238000000034 method Methods 0.000 title claims abstract description 202
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 176
- 239000002773 nucleotide Substances 0.000 title claims abstract description 174
- 239000000090 biomarker Substances 0.000 claims abstract description 113
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 107
- 201000010099 disease Diseases 0.000 claims abstract description 86
- 238000001514 detection method Methods 0.000 claims abstract description 76
- 238000005259 measurement Methods 0.000 claims abstract description 35
- 238000003745 diagnosis Methods 0.000 claims abstract description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 122
- 210000004027 cell Anatomy 0.000 claims description 115
- 239000002585 base Substances 0.000 claims description 103
- 201000011510 cancer Diseases 0.000 claims description 101
- 210000002381 plasma Anatomy 0.000 claims description 80
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 63
- 210000002966 serum Anatomy 0.000 claims description 63
- 210000001124 body fluid Anatomy 0.000 claims description 59
- 239000010839 body fluid Substances 0.000 claims description 58
- 239000011230 binding agent Substances 0.000 claims description 49
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 claims description 47
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 35
- 239000002777 nucleoside Substances 0.000 claims description 32
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 32
- 230000027455 binding Effects 0.000 claims description 30
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 29
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 28
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 28
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 28
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 28
- 238000012544 monitoring process Methods 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 19
- 229940104302 cytosine Drugs 0.000 claims description 16
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 15
- 229930024421 Adenine Natural products 0.000 claims description 14
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 14
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 14
- 229930010555 Inosine Natural products 0.000 claims description 14
- 229960000643 adenine Drugs 0.000 claims description 14
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 14
- 229960003786 inosine Drugs 0.000 claims description 14
- 210000004072 lung Anatomy 0.000 claims description 14
- 229940113082 thymine Drugs 0.000 claims description 14
- 229940035893 uracil Drugs 0.000 claims description 14
- 229940075420 xanthine Drugs 0.000 claims description 14
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 13
- 208000011231 Crohn disease Diseases 0.000 claims description 13
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 12
- 208000019693 Lung disease Diseases 0.000 claims description 10
- 230000001684 chronic effect Effects 0.000 claims description 10
- 206010009887 colitis Diseases 0.000 claims description 10
- 210000000496 pancreas Anatomy 0.000 claims description 8
- 210000000481 breast Anatomy 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 210000002307 prostate Anatomy 0.000 claims description 7
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 210000000214 mouth Anatomy 0.000 claims description 5
- 210000002784 stomach Anatomy 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 4
- 210000002429 large intestine Anatomy 0.000 claims description 4
- 230000000414 obstructive effect Effects 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- CLGFIVUFZRGQRP-UHFFFAOYSA-N 7,8-dihydro-8-oxoguanine Chemical compound O=C1NC(N)=NC2=C1NC(=O)N2 CLGFIVUFZRGQRP-UHFFFAOYSA-N 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 148
- 239000000523 sample Substances 0.000 description 100
- 108010033040 Histones Proteins 0.000 description 89
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 39
- 238000012360 testing method Methods 0.000 description 36
- 238000003018 immunoassay Methods 0.000 description 30
- 238000003556 assay Methods 0.000 description 26
- 230000007067 DNA methylation Effects 0.000 description 24
- 102000006947 Histones Human genes 0.000 description 23
- 239000003446 ligand Substances 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 21
- 239000012491 analyte Substances 0.000 description 20
- 108010077544 Chromatin Proteins 0.000 description 19
- 210000003483 chromatin Anatomy 0.000 description 19
- 238000012986 modification Methods 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 230000004048 modification Effects 0.000 description 15
- 239000012472 biological sample Substances 0.000 description 14
- 208000029742 colonic neoplasm Diseases 0.000 description 14
- 206010009944 Colon cancer Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 208000003445 Mouth Neoplasms Diseases 0.000 description 12
- 210000003040 circulating cell Anatomy 0.000 description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 201000005202 lung cancer Diseases 0.000 description 11
- 208000020816 lung neoplasm Diseases 0.000 description 11
- 230000011987 methylation Effects 0.000 description 11
- 238000007069 methylation reaction Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 102100023919 Histone H2A.Z Human genes 0.000 description 10
- 101000905054 Homo sapiens Histone H2A.Z Proteins 0.000 description 10
- 230000002583 anti-histone Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 10
- 238000004393 prognosis Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- BDJRBEYXGGNYIS-UHFFFAOYSA-N Nonanedioid acid Natural products OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 102100039869 Histone H2B type F-S Human genes 0.000 description 8
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 8
- 238000013019 agitation Methods 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 230000004481 post-translational protein modification Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011534 wash buffer Substances 0.000 description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
- 239000013060 biological fluid Substances 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 238000003748 differential diagnosis Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 201000002528 pancreatic cancer Diseases 0.000 description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 230000003278 mimic effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 102100030670 Core histone macro-H2A.2 Human genes 0.000 description 5
- 101710185000 Core histone macro-H2A.2 Proteins 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000013198 immunometric assay Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 108091023037 Aptamer Proteins 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 238000002967 competitive immunoassay Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000004811 liquid chromatography Methods 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 208000000649 small cell carcinoma Diseases 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 108091029523 CpG island Proteins 0.000 description 3
- 108091029430 CpG site Proteins 0.000 description 3
- 230000006429 DNA hypomethylation Effects 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001973 epigenetic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 2
- QSKPIOLLBIHNAC-UHFFFAOYSA-N 2-chloro-acetaldehyde Chemical compound ClCC=O QSKPIOLLBIHNAC-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 238000007400 DNA extraction Methods 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 108010022894 Euchromatin Proteins 0.000 description 2
- 108010034791 Heterochromatin Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000220259 Raphanus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- 108050002584 Septin 9 Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 229960001570 ademetionine Drugs 0.000 description 2
- 238000012575 bio-layer interferometry Methods 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000003822 cell turnover Effects 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- 239000000104 diagnostic biomarker Substances 0.000 description 2
- 210000000632 euchromatin Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003197 gene knockdown Methods 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 210000004458 heterochromatin Anatomy 0.000 description 2
- 238000007031 hydroxymethylation reaction Methods 0.000 description 2
- 230000006607 hypermethylation Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 108010034959 macroH2A histone Proteins 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 description 1
- ZALMSPFXLKMWDY-GMJFWCJPSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(1-hydroxyethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1[C@H](O)[C@@H](C(O)C)O[C@H]1N1C(=O)N=C(N)C=C1 ZALMSPFXLKMWDY-GMJFWCJPSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- RWWZYORFHGIOOC-UHFFFAOYSA-N 5-chloro-6-[4-(2-hydroxyethyl)piperidin-1-yl]-1h-pyrimidine-2,4-dione Chemical compound C1CC(CCO)CCN1C1=NC(O)=NC(O)=C1Cl RWWZYORFHGIOOC-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 description 1
- 101100450031 Caenorhabditis elegans htz-1 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 108091030081 DNA N(4)-methylcytosine Proteins 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 101001084710 Drosophila melanogaster Histone H2A.v Proteins 0.000 description 1
- 102100024739 E3 ubiquitin-protein ligase UHRF1 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 101710166728 Histone H3 Proteins 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 description 1
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 1
- 101000760417 Homo sapiens E3 ubiquitin-protein ligase UHRF1 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108020004446 Long Interspersed Nucleotide Elements Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000012060 Septin 9 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical class OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000006718 epigenetic regulation Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000001948 isotopic labelling Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000011338 personalized therapy Methods 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000010833 quantitative mass spectrometry Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530295P | 2011-09-01 | 2011-09-01 | |
| US61/530,295 | 2011-09-01 | ||
| GB1115095.0 | 2011-09-01 | ||
| GBGB1115095.0A GB201115095D0 (en) | 2011-09-01 | 2011-09-01 | Method for detecting nucleosomes containing nucleotides |
| PCT/GB2012/052128 WO2013030577A1 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012300641A1 AU2012300641A1 (en) | 2014-03-06 |
| AU2012300641B2 true AU2012300641B2 (en) | 2017-09-28 |
Family
ID=44882046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012300641A Ceased AU2012300641B2 (en) | 2011-09-01 | 2012-08-31 | Method for detecting nucleosomes containing nucleotides |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10900064B2 (enExample) |
| EP (2) | EP2751568B1 (enExample) |
| JP (1) | JP6322845B2 (enExample) |
| KR (1) | KR102074528B1 (enExample) |
| CN (1) | CN104067124B (enExample) |
| AU (1) | AU2012300641B2 (enExample) |
| BR (1) | BR112014005087B1 (enExample) |
| CA (1) | CA2845993C (enExample) |
| DK (1) | DK2751568T3 (enExample) |
| ES (1) | ES2717659T3 (enExample) |
| GB (1) | GB201115095D0 (enExample) |
| HR (1) | HRP20190533T1 (enExample) |
| HU (1) | HUE043386T2 (enExample) |
| MX (1) | MX364410B (enExample) |
| PL (1) | PL2751568T3 (enExample) |
| PT (1) | PT2751568T (enExample) |
| RU (2) | RU2014112350A (enExample) |
| SG (2) | SG11201400270PA (enExample) |
| TR (1) | TR201904386T4 (enExample) |
| WO (1) | WO2013030577A1 (enExample) |
| ZA (1) | ZA201401295B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US10081839B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US10083273B2 (en) | 2005-07-29 | 2018-09-25 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| CN102171565B (zh) | 2008-08-04 | 2015-04-29 | 纳特拉公司 | 等位基因调用和倍性调用的方法 |
| US20120185176A1 (en) | 2009-09-30 | 2012-07-19 | Natera, Inc. | Methods for Non-Invasive Prenatal Ploidy Calling |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| CA2798758C (en) | 2010-05-18 | 2019-05-07 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| ES2770342T3 (es) | 2010-12-22 | 2020-07-01 | Natera Inc | Procedimientos para pruebas prenatales no invasivas de paternidad |
| CA2824387C (en) | 2011-02-09 | 2019-09-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| EP2775304A1 (en) * | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Methods for detecting inflammatory disorder |
| US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
| US10577655B2 (en) | 2013-09-27 | 2020-03-03 | Natera, Inc. | Cell free DNA diagnostic testing standards |
| WO2015048535A1 (en) * | 2013-09-27 | 2015-04-02 | Natera, Inc. | Prenatal diagnostic resting standards |
| US12492429B2 (en) | 2014-04-21 | 2025-12-09 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| EP3561075A1 (en) | 2014-04-21 | 2019-10-30 | Natera, Inc. | Detecting mutations in tumour biopsies and cell-free samples |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| WO2016049936A1 (en) * | 2014-09-30 | 2016-04-07 | Bgi Shenzhen Co., Limited | Biomarkers for rheumatoid arthritis and usage therof |
| EP3809140A1 (en) | 2014-10-29 | 2021-04-21 | Belgian Volition SPRL | Method for the enrichment of circulating tumor dna |
| WO2016128383A1 (en) * | 2015-02-10 | 2016-08-18 | B.R.A.H.M.S Gmbh | Free histone proteins as biomarkers |
| EP4428863A3 (en) | 2015-05-11 | 2024-12-11 | Natera, Inc. | Methods and compositions for determining ploidy |
| AU2016264102A1 (en) | 2015-05-18 | 2017-12-21 | Karius, Inc. | Compositions and methods for enriching populations of nucleic acids |
| GB201511542D0 (en) * | 2015-07-01 | 2015-08-12 | Singapore Volition Pte Ltd | Use of cell free nucleosomes as biomarkers |
| GB201511512D0 (en) * | 2015-07-01 | 2015-08-12 | Singapore Volition Pte Ltd | Use of cell-free nucleosomes as biomarkers |
| GB201518665D0 (en) | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for enrichment of cell free nucleosomes |
| GB201518674D0 (en) * | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for detecting nuleosomes containing histone modifications and variants |
| GB201604806D0 (en) * | 2016-03-22 | 2016-05-04 | Singapore Volition Pte Ltd | Method of identifying a cancer of unknown origin |
| DK3443119T3 (da) | 2016-04-15 | 2022-05-23 | Natera Inc | Fremgangsmåde til bestemmelse af lunge cancer |
| CN107858416B (zh) * | 2016-09-19 | 2021-05-28 | 深圳华大生命科学研究院 | 用于子宫内膜异位症检测的生物标志物组合及其应用 |
| WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| US10894976B2 (en) | 2017-02-21 | 2021-01-19 | Natera, Inc. | Compositions, methods, and kits for isolating nucleic acids |
| CN107164508A (zh) * | 2017-06-16 | 2017-09-15 | 上海易毕恩基因科技有限公司 | 用于检测肝癌的基因标志物及其用途 |
| CN107385051A (zh) * | 2017-08-04 | 2017-11-24 | 上海易毕恩生物技术有限公司 | 用于检测肝肿瘤良恶性的基因标志物、试剂盒及检测方法 |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| US12398389B2 (en) | 2018-02-15 | 2025-08-26 | Natera, Inc. | Methods for isolating nucleic acids with size selection |
| AU2019228625B2 (en) * | 2018-03-01 | 2024-11-07 | Epicypher, Inc. | Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes |
| JP7573443B2 (ja) | 2018-04-14 | 2024-10-25 | ナテラ， インコーポレイテッド | 循環腫瘍ｄｎａの個別化された検出を用いる癌検出およびモニタリングの方法 |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| GB201818963D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Methof for the detection of prostate cancer |
| GB201818965D0 (en) | 2018-11-21 | 2019-01-09 | Belgian Volition Sprl | Method for the detection of colorectal cancer |
| GB201906201D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Voltion Sprl | Method for the detection of protate cancer |
| GB201906199D0 (en) | 2019-05-02 | 2019-06-19 | Belgian Volition Sprl | Method for the detection of cancer |
| EP3980559A1 (en) | 2019-06-06 | 2022-04-13 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
| GB201912251D0 (en) | 2019-08-27 | 2019-10-09 | Belgian Volition Sprl | Method of isolating circulating nucleosomes |
| WO2021038010A1 (en) | 2019-08-27 | 2021-03-04 | Belgian Volition Sprl | Method of isolating circulating nucleosomes |
| BR112022010774A2 (pt) | 2019-12-02 | 2022-08-23 | Belgian Volition Srl | Uso de nucleossomos livres de células como biomarcadores |
| EP4121551A1 (en) | 2020-03-20 | 2023-01-25 | Belgian Volition SRL | Triaging method using cell free nucleosome levels |
| TW202238131A (zh) | 2020-11-25 | 2022-10-01 | 比利時商比利時意志有限公司 | 測量無細胞核蛋白染色質片段之方法 |
| TW202242145A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析 |
| TW202242130A (zh) | 2020-12-29 | 2022-11-01 | 比利時商比利時意志有限公司 | 循環轉錄因子分析 |
| TW202242146A (zh) | 2021-01-13 | 2022-11-01 | 比利時商比利時意志有限公司 | 肺癌的檢測方法 |
| GB202108185D0 (en) | 2021-06-08 | 2021-07-21 | Belgian Volition Sprl | Standardisation of nucleosome assays using biologically derived calibrants |
| GB202108452D0 (en) | 2021-06-14 | 2021-07-28 | Belgian Volition Sprl | Triaging method using cell free nucleosome levels |
| JP2024542996A (ja) | 2021-10-29 | 2024-11-19 | ベルジアン ボリション エスアールエル | 均一系免疫アッセイ法 |
| GB202117799D0 (en) | 2021-12-09 | 2022-01-26 | Belgian Volition Srl | Method for the detection of blood cancer |
| EP4490323A1 (en) | 2022-03-11 | 2025-01-15 | Belgian Volition SRL | Differential diagnosis method |
| GB202205212D0 (en) | 2022-04-08 | 2022-05-25 | Belgian Volition Sprl | Method for transplant organ health assessment |
| WO2024042210A1 (en) | 2022-08-25 | 2024-02-29 | Belgian Volition Srl | Method for measuring cell free chromatin |
| EP4639165A1 (en) | 2022-12-19 | 2025-10-29 | Belgian Volition SRL | Assessment of biological samples for nucleic acid analysis |
| GB202300607D0 (en) | 2023-01-16 | 2023-03-01 | Belgian Volition Srl | Proteins and methods for isolating circulating nucleosomes |
| GB202303562D0 (en) | 2023-03-10 | 2023-04-26 | Belgian Volition Sprl | Sample collection for liquid biopsy |
| WO2025061853A1 (en) | 2023-09-19 | 2025-03-27 | Belgian Volition Srl | Lateral flow test device |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999047924A1 (en) * | 1998-03-18 | 1999-09-23 | Roche Diagnostics Gmbh | Detection of apoptotic products |
| WO2005019826A1 (en) * | 2003-08-18 | 2005-03-03 | Chroma Therapeutics Limited | Detection of histone modification in cell-free nucleosomes |
| WO2005040814A1 (en) * | 2003-10-14 | 2005-05-06 | Cancer Research Technology Limited | Methods and means of cancer detection by histone modification |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2652901A1 (fr) | 1989-10-11 | 1991-04-12 | Pasteur Institut | Complexes biologiques a base de nucleosomes, et leurs applications, notamment dans le domaine du diagnostic in vitro du lupus erythemateux dissemine (led). |
| US6630301B1 (en) * | 1997-03-14 | 2003-10-07 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum |
| PT938320E (pt) * | 1996-03-26 | 2010-09-22 | Michael S Kopreski | Método que permite a utilização de arn extracelular extraído de plasma ou de soro para detectar, monitorizar ou avaliar o cancro |
| NL1014106C2 (nl) | 2000-01-18 | 2001-07-20 | Univ Amsterdam | Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit. |
| ATE419392T1 (de) | 2003-07-04 | 2009-01-15 | Johnson & Johnson Res Pty Ltd | Verfahren zum nachweis von alkyliertem cytosin in dna |
| US7741086B2 (en) * | 2004-12-16 | 2010-06-22 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog LSD1 |
| DE102005034628B4 (de) * | 2005-07-19 | 2007-08-23 | Epigenomics Ag | Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA |
| US20090264306A1 (en) | 2005-10-27 | 2009-10-22 | Curators Of The University Of Missouri | Dna methylation biomarkers in lymphoid and hematopoietic malignancies |
| WO2007049286A1 (en) * | 2005-10-27 | 2007-05-03 | Tata Memorial Centre | A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma |
| EP1959997A4 (en) | 2005-11-28 | 2009-12-23 | Medimmune Llc | ANTAGONISTS OF HMGB1 AND / OR RAGE AND METHOD OF USE THEREOF |
| DE102006035600B3 (de) | 2006-07-27 | 2007-11-08 | Epigenomics Ag | Verfahren zum Nachweis eines Methylierungsmusters |
| US20080131954A1 (en) * | 2006-11-30 | 2008-06-05 | Canon U.S. Life Sciences, Inc. | Method of Separating Target DNA from Mixed DNA |
| EP2147124A4 (en) * | 2007-04-11 | 2010-07-14 | Manuel Esteller | EPIGENETIC BIOMARKERS FOR EARLY DETECTION, EFFICIENT TREATMENT AND RETENTION OF CANCER |
| US7608402B2 (en) * | 2008-01-10 | 2009-10-27 | Weiwei Li | DNA methylation specific signal amplification |
| WO2009115313A1 (en) | 2008-03-19 | 2009-09-24 | Oryzon Genomics, S.A. | Method and composition for methylation analysis |
| RU2011125306A (ru) | 2008-11-21 | 2012-12-27 | Юнивёрсити Оф Копенгаген | Праймирование иммунного ответа |
| CN102460173A (zh) | 2009-04-14 | 2012-05-16 | 加利福尼亚大学董事会 | 组蛋白修饰用于癌症的临床诊断和预后 |
| WO2011017681A2 (en) | 2009-08-06 | 2011-02-10 | Cornell University | Device and method for molecular analysis |
| EP2561367A1 (en) | 2010-04-22 | 2013-02-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations |
| EP2577313A1 (en) | 2010-06-03 | 2013-04-10 | Porto Conte Ricerche S.r.l. | Biomarkers for lung neuroendocrine tumors |
| FI20105715A0 (fi) | 2010-06-18 | 2010-06-18 | Helsingin Yliopisto | Asetyloituun HMGB1:een sitoutuva polyklonaalinen vasta-aine |
| CN101955998A (zh) * | 2010-07-20 | 2011-01-26 | 赵英仁 | 一种血浆游离dna水平检测肝细胞坏死程度的方法 |
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| GB201115098D0 (en) * | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| SG10201604081YA (en) * | 2011-12-07 | 2016-07-28 | Singapore Volition Pte Ltd | Method for detecting nucleosome adducts |
| EP3757210B1 (en) | 2012-03-02 | 2022-08-24 | Sequenom, Inc. | Methods for enriching cancer nucleic acid from a biological sample |
| GB201303575D0 (en) | 2013-02-28 | 2013-04-10 | Singapore Volition Pte Ltd | Method for detecting histone modifications in nucleosomes |
-
2011
- 2011-09-01 GB GBGB1115095.0A patent/GB201115095D0/en not_active Ceased
-
2012
- 2012-08-31 CA CA2845993A patent/CA2845993C/en active Active
- 2012-08-31 RU RU2014112350/15A patent/RU2014112350A/ru unknown
- 2012-08-31 US US14/239,783 patent/US10900064B2/en active Active
- 2012-08-31 EP EP12756549.7A patent/EP2751568B1/en active Active
- 2012-08-31 PT PT12756549T patent/PT2751568T/pt unknown
- 2012-08-31 HR HRP20190533TT patent/HRP20190533T1/hr unknown
- 2012-08-31 ES ES12756549T patent/ES2717659T3/es active Active
- 2012-08-31 HU HUE12756549A patent/HUE043386T2/hu unknown
- 2012-08-31 BR BR112014005087-2A patent/BR112014005087B1/pt not_active IP Right Cessation
- 2012-08-31 SG SG11201400270PA patent/SG11201400270PA/en unknown
- 2012-08-31 DK DK12756549.7T patent/DK2751568T3/en active
- 2012-08-31 KR KR1020147008108A patent/KR102074528B1/ko not_active Expired - Fee Related
- 2012-08-31 CN CN201280053555.1A patent/CN104067124B/zh not_active Expired - Fee Related
- 2012-08-31 PL PL12756549T patent/PL2751568T3/pl unknown
- 2012-08-31 TR TR2019/04386T patent/TR201904386T4/tr unknown
- 2012-08-31 EP EP18212025.3A patent/EP3483608B1/en active Active
- 2012-08-31 MX MX2014002443A patent/MX364410B/es active IP Right Grant
- 2012-08-31 JP JP2014527737A patent/JP6322845B2/ja active Active
- 2012-08-31 WO PCT/GB2012/052128 patent/WO2013030577A1/en not_active Ceased
- 2012-08-31 RU RU2017126701A patent/RU2687483C2/ru active
- 2012-08-31 SG SG10201601153RA patent/SG10201601153RA/en unknown
- 2012-08-31 AU AU2012300641A patent/AU2012300641B2/en not_active Ceased
-
2014
- 2014-02-20 ZA ZA2014/01295A patent/ZA201401295B/en unknown
-
2020
- 2020-05-15 US US16/875,856 patent/US20200347435A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999047924A1 (en) * | 1998-03-18 | 1999-09-23 | Roche Diagnostics Gmbh | Detection of apoptotic products |
| WO2005019826A1 (en) * | 2003-08-18 | 2005-03-03 | Chroma Therapeutics Limited | Detection of histone modification in cell-free nucleosomes |
| WO2005040814A1 (en) * | 2003-10-14 | 2005-05-06 | Cancer Research Technology Limited | Methods and means of cancer detection by histone modification |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230116530A1 (en) | Method for detecting nucleosomes containing histone variants | |
| US20200347435A1 (en) | Method for detecting nucleosomes containing nucleotides | |
| US9222937B2 (en) | Method for detecting nucleosomes | |
| US20170003296A1 (en) | Method for detecting histone modifications in nucleosomes | |
| HK40008468A (en) | Method for detecting nucleosomes containing nucleotides | |
| HK1253354B (en) | Method for detecting nucleosomes containing histone variants | |
| HK1199760B (en) | Method for detecting nucleosomes containing nucleotides | |
| HK1199758B (en) | Method for detecting nucleosomes containing histone variants | |
| HK1199761B (en) | Method for detecting nucleosomes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: BELGIAN VOLITION SPRL Free format text: FORMER APPLICANT(S): SINGAPORE VOLITION PTE LIMITED |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |